Tag: IT

Transaction in Own Shares

Los Angeles, June 05, 2026 (GLOBE NEWSWIRE) -- Global charging brand INIU has officially launched its new SnapGo Air 10000mAh Magnetic Power Bank. As one of the most well-rounded magnetic power banks in terms of functionality, SnapGo Air embodies the philosophy “Sleek Power. Solid Confidence.”By combining faster wireless charging, an ultra-slim profile, and versatile power delivery, the new model sets a new benchmark for everyday portable energy.

SHANGHAI, June 05, 2026 (GLOBE NEWSWIRE) -- Inside the bustling halls of the 19th SNEC Exhibition, Sigenergy showcased the future of clean energy. Under its defining "AI in All" strategy, the company unveiled a complete portfolio of smart solar-plus-storage solutions, proving how deep artificial intelligence can transform utility grids, commercial spaces, and residential homes into highly synchronized, autonomous energy ecosystems.

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Keel Infrastructure Corp. (NASDAQ/TSX: KEEL), a North American digital and energy infrastructure company (“Keel” or the “Company”), today announced that it has priced its offering of $400 million aggregate principal amount of 1.250% convertible senior notes due 2032 (the “Convertible Notes”). Keel has also granted the initial purchasers of the Convertible Notes an option to purchase, for a 13-day period beginning on and including the date on which the Convertible Notes are first issued, up to an additional $58 million aggregate principal amount of the Convertible Notes. The aggregate principal amount of the offering was increased from the previously announced offering size of $350 million (or $408 million if the initial purchasers exercise their option to purchase the option in full). The payment obligations under the notes will be fully and unconditionally guaranteed, on a senior unsecured basis, by Bitfarms Ltd., a wholly owned subsidiary of Keel. The offering is expected to close, subject to market and other closing conditions on or about June 9, 2026.

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels